The U.S. Food and Drug Administration has once again declined to approve Avenue Therapeutics Inc’s (NASDAQ: ATXI) painkiller tramadol noting that it was not safe for the intended population. The announcement saw Avenue’s share drop by 5% in premarket trading.  According to the FDA, intravenous (IV) tramadol showed delayed and […]